Pfizer's Stock Falls Ill as the Dow Tumbles
AbbVie's stock falls after its market-shaking deal to acquire Shire on Friday.
Welcome to Ireland, AbbVie
AbbVie paid a whopping $54.8 billion for Shire, but it's a good deal--assuming the U.S. Congress doesn't pass a law undercutting the tax gains.
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.